Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC-Reference-Cited by-同舟云学术

Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC

Published:2019-08 Issue:8 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Barnes Melissa D.¹²,Taracila Magdalena A.¹²,Good Caryn E.²³,Bajaksouzian Saralee²³,Rojas Laura J.¹²⁴,van Duin David⁵,Kreiswirth Barry N.⁶,Jacobs Michael R.²³,Haldimann Andreas⁷,Papp-Wallace Krisztina M.¹²⁸,Bonomo Robert A.¹²⁸⁴⁹

Affiliation:

1. Louis Stokes Cleveland VA Medical Center, Research Service, Cleveland, Ohio, USA

2. Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA

3. Department of Pathology, Cleveland Medical Center Hospitals, Cleveland, Ohio, USA

4. Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, Ohio, USA

5. University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA

6. Rutgers University, Public Health Research Institute Tuberculosis Center, New Jersey Medical School, Newark, New Jersey, USA

7. Roche Pharma Research and Early Development, Immunology, Infectious Diseases and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland

8. Department of Biochemistry, Case Western Reserve University, Cleveland, Ohio, USA

9. Department of Pharmacology, Case Western Reserve University, Cleveland, Ohio, USA

Abstract

Carbapenem-resistant Enterobacteriaceae (CRE) are resistant to most antibiotics, making CRE infections extremely difficult to treat with available agents. Klebsiella pneumoniae carbapenemases (KPC-2 and KPC-3) are predominant carbapenemases in CRE in the United States. Nacubactam is a bridged diazabicyclooctane (DBO) β-lactamase inhibitor that inactivates class A and C β-lactamases and exhibits intrinsic antibiotic and β-lactam “enhancer” activity against Enterobacteriaceae .

Funder

Veterans Affairs Merit Review Program Award

HHS | NIH | National Institute of Allergy and Infectious Diseases

F. Hoffmann-La Roche

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00432-19

Reference45 articles.

1. U.S. Department of Health and Human Services and Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States. U.S. Department of Health and Human Services and Centers for Disease Control and Prevention Atlanta GA. http://www.cdc./drugresistance/threat-report-2013/index.html.

2. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

3. First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate

4. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment

5. Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Agents Are Coming, and So Is the Resistance;Antibiotics;2024-07-13

2. Evolving resistance landscape in gram‐negative pathogens: An update on β‐lactam and β‐lactam‐inhibitor treatment combinations for carbapenem‐resistant organisms;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-07

3. Therapies in preclinical and in early clinical development for the treatment of urinary tract infections: from pathogens to therapies;Expert Opinion on Investigational Drugs;2024-05-09

4. Electric Fields Are a Key Determinant of Carbapenemase Activity in Class A β-Lactamases;ACS Catalysis;2024-04-23

5. Role of β-Lactamase Inhibitors as Potentiators in Antimicrobial Chemotherapy Targeting Gram-Negative Bacteria;Antibiotics;2024-03-15